Journal
GENE THERAPY
Volume 19, Issue 6, Pages 622-629Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/gt.2012.17
Keywords
angiogenesis; clinical trial; myocardial infarction; VEGF
Categories
Funding
- European Research Council (ERC) [20090506]
Ask authors/readers for more resources
Despite the enormous progress made in terms of prevention and early intervention, a pressing need remains to develop innovative therapeutic strategies for ischemic cardiovascular disorders, including acute myocardial infarction, chronic cardiac ischemia, peripheral artery disease and stroke. The induction of new blood vessel formation by delivering angiogenic genes to ischemic tissues continues to appear as a promising, alternative strategy to currently available therapies. In aspiring to induce therapeutic angiogenesis, the members of the vascular endothelial growth factor (VEGF) family have long been recognized as major molecular tools. Remarkably, VEGF family members have recently been recognized to also exert multiple, non-angiogenic effects on various cell types, including neurons, skeletal muscle and cardiac cells. Here, we critically review the VEGF-based therapies that have already reached clinical experimentation and highlight the pleiotropic activities of VEGF factors that might create new opportunities for therapeutic application. Gene Therapy (2012) 19, 622-629; doi:10.1038/gt.2012.17; published online 1 March 2012
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available